[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"shingles\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:shingles":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":16,"targetDuration":4,"studyType":19,"phases":20,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":31,"leadSponsor":33,"locationsCount":5},"100481826",false,"NCT05554068","Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients","Phase II, Non-randomized, Open-label Study to Assess the Immunogenicity and Clinical Efficacy of the Recombinant Zoster Vaccine for Recipients of an Allogeneic Hematopoietic Stem Cell Transplant","Inclusion Criteria:\n\n* Age ≥18 years\n* ≥ 12 months and ≤ 36 months post-AlloSCT\n* Donor sources: matched related, matched unrelated, cord blood\n* Any malignant hematological disease including acute leukemia, myelodysplastic syndrome, non-Hodgkin's lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia, multiple myeloma, and myeloproliferative disorders.\n* Any conditioning regimen\n* Any planned immunosuppressive prophylactic regimen\n* Patients with chronic graft-versus-host disease on stable immunosuppression\n* Ability to understand and the willingness to sign a written informed consent.\n* Negative pregnancy test in female patients of childbearing potential\n\nExclusion Criteria:\n\n* Patients who had zoster after an allogeneic transplant and prior to enrollment\n* Patients who are currently pregnant\n* History of allergic reactions attributed to compounds of similar chemical or biologic composition to the recombinant zoster vaccine, Shingrix, or other agents used in study.\n* Patients who have had a relapse of their primary hematological disease\n* Previous allogeneic stem cell transplantation\n* Acute disease at the time of vaccination\n* Thrombocytopenia that in the judgment of the investigator would make intramuscular injection unsafe.","ALL",{"count":17,"type":18},100,"ESTIMATED","INTERVENTIONAL",[21],"PHASE2","This is a phase II study that will examine the immunogenicity of the Shingrix vaccine in patients following an allogeneic stem cell transplant.",[24],"Shingles","RECRUITING","2023-03-07",{"date":28,"type":29},"2023-03-08","ACTUAL",{"date":26,"type":29},{"date":32,"type":18},"2026-11-01",{"name":34,"class":35},"Loyola University","OTHER",""]